Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT
RECENT BUSINESS DEVELOPMENT PROGRESS IN THAILAND

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

STRATEGIC PARTNERSHIP WITH N HEALTH

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that the Company has on December 15, 2025 entered into a strategic partnership (the "**Strategic Partnership**") with N Health ("**N Health**"), a healthcare solutions provider and a member of Bangkok Dusit Medical Services (BDMS) Group, Thailand's largest healthcare provider. The Strategic Partnership is aimed at introducing advanced microRNA (miRNA) cancer screening solutions to Thailand, and signifies a major step forward in enhancing early cancer detection and improving patient outcomes across Thailand and the wider region.

The Strategic Partnership taps into the Thailand health check-up market which is experiencing significant growth. It is projected to reach approximately US$500 million by 2030 with a compound annual growth rate of 9.2% from 2025, with specialized health check-ups as the fastest-growing segment, indicating strong demand for advanced and targeted screening solutions. This robust market, coupled with increasing awareness of preventive healthcare and a rising prevalence of chronic conditions, creates an ideal environment for adopting innovative diagnostic technologies such as the Company's miRNA tests.

Driven by a shared commitment to healthcare advancement, the Strategic Partnership will leverage the Company's cutting-edge miRNA technology and innovative screening solutions such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer. Through the Strategic Partnership, the Company's cancer screening tests will be introduced across nearly 60 hospitals within N Health's network, with a scalable model that supports broader access to early disease detection across Thailand and Southeast Asia, contributing to improved standards of cancer care in the region.

N Health aims to strengthen its role in delivering end-to-end healthcare solutions while expanding access to advanced cancer screening nationwide through the Strategic Partnership, which will also enable N Health to integrate advanced cancer risk assessment into preventive care, thereby supporting earlier intervention and promoting healthier aging across Thailand amid its transition into an aging society. In addition, the Strategic Partnership will transform how cancer is identified and managed in Thailand, while paving the way for the Company's growth throughout Southeast Asia.

REGULATORY APPROVAL OF TWO AT-HOME DIAGNOSTIC TEST KITS

The Board further announces that following the Thailand FDA's approval in October 2025 and December 2025, respectively, the Company has on January 9, 2026 launched its new range of at-home screening test kits in Thailand, namely HELICORapid, which is designed to detect Helicobacter pylori (H. pylori) infection, a major and strongest known risk factor for stomach cancer, and FITRapid, which is designed to detect fecal occult blood, an indicator of cancer or polyps in the colon or rectum. These two direct-to-consumer, cancer risk factor tests are designed to complement and synergize with the Company's core innovative miRNA cancer screening solutions, including the Thailand FDA approved GASTROClear™ and its pipeline colorectal and multi-cancer blood tests, and enable the Company to expand its sales and marketing efforts to the consumer sector.

The new test kits are the first of their kind in the Thailand market, featuring an innovative, single-device design that integrates sample collection and testing into one streamlined unit. This proprietary design, protected by registered intellectual property, minimizes handling steps and significantly reduces the risk of contamination and user error, which is an especially critical improvement when working with stool-based samples. By offering easy-to-use, hygienic, and reliable at-home tests through modern trade and pharmacy channels, the Company is making preventive healthcare more accessible to the wider population, without compromising on scientific rigor or user safety.

Fecal occult blood testing is widely used as a frontline screening approach for colorectal abnormalities, while H. pylori infection is a well-established risk factor for gastric diseases, especially gastric cancer. These two indicators are also closely associated with gastrointestinal diseases and are widely recognized as important markers for the early detection of gastric and colorectal cancers. By enabling earlier awareness and encouraging timely medical follow-up, these at-home test kits serve as an important first-line screening tool, complementing the Company's broader early cancer detection ecosystem, which includes advanced molecular diagnostics.

To ensure widespread accessibility, the Company will distribute these test kits through modern trade outlets and pharmacy networks across Thailand, aligning with evolving consumer healthcare behaviors and the growing demand for preventive, self-administered diagnostics. This launch underscores the Company's mission to democratize early detection, empowering individuals with practical tools to take charge of their health while supporting healthcare systems through earlier intervention and improved disease awareness. It also represents a significant milestone in the Company's long-term strategy to expand early cancer detection beyond hospitals and laboratories, making reliable screening solutions accessible in everyday consumer settings.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, January 9, 2026

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.